Rasburicase and tumor lysis syndrome: Lower dosage, consideration of indications, and hyperhydration

Journal of Clinical Oncology

Volumn 29, Issue 3, 2011, Pages

  Darmon, Michaël ^a   Guichard, Isabelle ^a   Vincent, François ^b  

^a Saint Etienne Hospital   (France)

^b AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; RASBURICASE; URIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; BURKITT LYMPHOMA; CHRONIC MYELOID LEUKEMIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE REDUCTION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; HYDRATION; LETTER; LOW DRUG DOSE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OPTIMAL DRUG DOSE; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOLID TUMOR; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL;

ADULT; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COSTS; GOUT SUPPRESSANTS; HUMANS; HYPERPHOSPHATEMIA; HYPERURICEMIA; TUMOR LYSIS SYNDROME; URATE OXIDASE;

EID: 79951969805     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.6751     Document Type: Letter

References (14)

1. Cortes J, Moore JO, Maziarz RT, et al: Control of plasma uric acid in adults at risk for tumor lysis syndrome: Efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone-Results of a multicenter phase III study. J Clin Oncol 20:4207-4213, 2010
2. Lee AC, Li CH, So KT, et al: Treatment of impending lumor lysis with single-dose rasburicase. Ann Pharmacother 37:1614-1617, 2003 (Pubitemid 37315101)
3. McDonnell AM, Lenz KL, Frei-Lahr DA, et al: Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy 26:806-812, 2006 (Pubitemid 43807632)
4. Liu CY, Sims-McCallum RP, Schiffer CA: A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leuk Res 29:463-465, 2005 (Pubitemid 40255822)
5. Trifilio S, Gordon L, Singhal S, et al: Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant 37:997-1001, 2006
6. Hutcherson DA, Gammon DC, Bhatt MS, et al: Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy 26:242-247, 2006 (Pubitemid 43201871)
7. Hummel M, Reiter S, Adam K, et al: Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase. Eur J Haematol 80:331-336, 2008 (Pubitemid 351347575)
8. Reeves DJ, Bestul DJ: Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer. Pharmacotherapy 28:685-690, 2008 (Pubitemid 351975371)
9. Campara M, Shord SS, Haaf CM: Single-dose rasburicase for tumour lysis syndrome in adults: Weight-based approach. J Clin Pharm Ther 34:207-213, 2009
10. Giraldez M, Puto K: A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults. Eur J Haematol 85:177-179, 2010
11. Trifilio SM, Pi J, Zook J, et al: Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies. Bone Marrow Transplant [epub ahead of print on September 6, 2010]
12. Cairo MS, Coiffier B, Reiter A, et al: Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: An expert TLS panel consensus. Br J Haematol 149:578-586, 2010
13. Darmon M, Guichard I, Vincent F, et al: Prognostic significance of acute renal injury in acute tumor lysis syndrome. Leuk Lymphoma 51:221-227, 2010
14. Coiffier B, Altman A, Pui CH, et al: Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review. J Clin Oncol 26:2767-2778, 2008